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TOTAL Trial: Although High Thrombus Burden 
Was an Important Predictor of Outcome in STEMI, 
Routine Thrombus Aspiration Did Not Improve 
Outcomes at 1 Year and Was Associated With an 
Increased Rate of Stroke  
Among 10,732 patients with STEMI randomized to 
routine manual thrombectomy versus PCI alone, the 
primary outcome of cardiovascular (CV) death, MI, 
cardiogenic shock, or heart failure at 1 year was similar 
with thrombus aspiration in patients with high (8.1% vs. 
8.3% thrombus aspiration; hazard ratio - HR: 0.97) or low 
thrombus burden (% vs. 5% thrombus aspiration; HR: 
1.22; interaction p=0.41). However, among patients with 
high thrombus burden, stroke at 1 month was more 
frequent with thrombus aspiration (31 / 0.7% thrombus 
aspiration vs 16 / 0.4% PCI alone, HR: 1.90). In the high 
thrombus burden group, thrombus aspiration did not 
improve 1-month (HR: 0.78; p=0.06) and 1-year CV 
mortality (HR: 0.88; p=0.25). Irrespective of treatment 
assignment, high thrombus burden was an independent 
predictor of death (HR: 1.78) (Jolly SS et al, J Am Coll 
Cardiol 2018;72: 1589–96).  
 
Meta-Analysis: Catheter Ablation of Atrial Fibrillation 
(AF) in Patients with Heart Failure (HF) was Superior 
to Conventional Drug Therapy in Improving All-Cause 
Mortality, HF Hospitalizations, LVEF, 6-Minute Walk 
Test Distance, VO2max, and Quality of Life, With an 
Increase, Albeit Non-significant, in Adverse Events  
Meta-analysis of 6 RCTs involving 775 patients 
indicated that compared with drug therapy, AF ablation 
reduced all-cause mortality (9% vs 17.6%; risk ratio -RR, 
0.52) and HF hospitalizations (16.4% vs 27.6%; RR, 0.60). 
Ablation improved left ventricular ejection fraction 
(LVEF) (mean difference, 6.95%), 6-minute walk test 
distance (mean difference, 20.93 m), peak oxygen 
consumption (VO2max) (mean difference, 3.17 mL/kg per 
minute), and quality of life (mean difference in Minnesota 
Living with Heart Failure Questionnaire score, −9.02 
points). Serious adverse events were more common in the 
ablation groups (7.2% vs 3.8%; RR, 1.68) (Turagam MK 
et al, Ann Int Med 2018, Dec 25).  
 
The Mitral Annulus Disjunction (MAD) Arrhythmic 
Syndrome 
 
Mitral annulus disjunction (MAD) is an abnormal 
atrial displacement of the mitral valve leaflet hinge point. 
MAD has been associated with mitral valve prolapse 
(MVP) and sudden cardiac death. Among 116 patients 
with MAD (age 49 ± 15 years; 60% female), palpitations 
were the most common symptom (71%), while severe 
arrhythmic events occurred in 14 (12%) patients. Patients 
with severe arrhythmic events were younger (age 37 ± 13 
years vs 51 ± 14 years; p=0.001), had lower ejection 
fraction (51 ± 5% vs 57 ± 7%; p=0.002) and had more 
frequently papillary muscle fibrosis (4 or 36% vs 6 or 9%; 
p=0.03). MVP was evident in 90 (78%) patients and was 
not associated with ventricular arrhythmia (Dejgaard LA 
et al, J Am Coll Cardiol 2018;72:1600-9). 
 
In Atrial Fibrillation (AF) Patients With Myocardial 
Infarction (MI) and/or After PCI, Non-Vitamin K Oral 
Anticoagulant (NOAC) in Combination With Dual 
Antiplatelet Therapy (DAPT) was Associated With a 
Significantly Decreased Risk of Bleeding and Similar 
Thromboembolic Protection Compared With Vitamin 
K Antagonist (VKA) in Combination With DAPT  
Among 3,222 patients, of whom 875 (27%) were 
treated with VKA+single antiplatelet therapy (SAPT), 595 
(18%) with NOAC+SAPT, 1,074 (33%) with VKA+ 
DAPT, and 678 (22%) with NOAC+DAPT, at 3 months, 
there was a significant difference in the absolute risk of MI 
associated with NOAC+SAPT compared with VKA+ 
SAPT (3-month absolute risk difference-ARD: −1.53%), 
with no significant differences found regarding bleeding, 
ischemic stroke, and all-cause mortality. Compared with 
VKA+DAPT, NOAC+DAPT was associated with a 
significantly reduced risk of bleeding (3-month ARD: 
−1.96%), with no significant difference in the absolute risk 
of all-cause mortality, stroke, or MI (p< 0.0001) (Sindet-
Pedersen C et al, J Am Coll Cardiol 2018; 72:1790-800)  
 
Home Monitoring for Fetal Heart Rhythm (FHRM) 
During Anti-Ro Pregnancies  
Fetal atrioventricular block (AVB) occurs in 2-4% of 
anti-Ro antibody–positive pregnancies between 18 and 26 
weeks and can develop in <24 h. Outcome of anti-Ro 
pregnancies was surveilled with twice-daily home fetal 
heart rhythm monitoring (FHRM) and surveillance 
echocardiography. Most mothers (273 of 315, 87%) 
completed the monitoring protocol. Abnormal FHRM was 
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detected in 21 mothers (6.7%) who sought medical 
attention >12h (n=7), 3-12h (n=9), or <3h (n=5) after 
abnormal FHRM; 18 fetuses had benign rhythms, and 3 
had second- or third-degree AVB. Treatment with oral 
dexamethasone and IV immunoglobulin of second-degree 
AVB<12h after abnormal FHRM restored sinus rhythm, 
but failed in 2 fetuses with complete AVB. Four fetuses 
had first-degree AVB diagnosed by echocardiography; 
none progressed to second-degree AVB (Cuneo et al, J Am 
Coll Cardiol 2018; 72:1940-51).  
 
Single-Stage, Complete Multivessel Percutaneous 
Revascularization is Associated With Better Long-
Term Survival Than Culprit Vessel–Only 
Revascularization in Patients With NSTEMI 
A total of 21,857 patients (58.3%) presented with 
NSTEMI and multivessel disease, of whom 11,737 (53.7%) 
underwent single-stage complete revascularization during 
PCI. Those undergoing complete revascularization were 
older and more likely to be male, diabetic, have renal disease 
and a history of previous MI/revascularization compared with 
the culprit-only revascularization group. Over a median of 4.1 
years, in-hospital major adverse cardiac event rates were 
similar (5.2% vs 4.8%; p=0.462), but mortality rates differed: 
22.5% complete revascularization vs 25.9% culprit vessel 
intervention (p=0.0005) (hazard ratio-HR: 0.90 by 
multivariate analysis and 0.89 by propensity matching 
(Rathod KS et al, J Am Coll Cardiol 2018; 72:1989-99).  
 
SURTAVI: In Patients With Symptomatic Severe 
Aortic Stenosis (AS) of Intermediate Surgical Risk, 30-
Day Rates of Stroke and Encephalopathy Were Higher 
After Surgical Valve Replacement (AVR) than After 
(TAVI) and Were Associated With Higher Mortality 
by 1 Year After Either Type of Procedure 
Among 1,660 intermediate risk AS patients, 864 had 
TAVI and 796 AVR. The rates of early (30-day) stroke and 
post-procedural encephalopathy were higher after AVR vs 
TAVI (5.4% vs 3.3%, p=0.031; 7.8% vs 1.6%, p< 0.001, 
respectively). At 1 year, the rate of stroke was not different 
(6.9% vs 5.2%; p=0.136). Early stroke and early encepha-
lopathy resulted in increased mortality at 1 year in both 
groups. Quality of life after an early stroke was lower in 
AVR at 30 days and similar at 6 and 12 months (Durko AP 
et al, J Am Coll Cardiol 2018;72:2109-19).  
 
PARTNER: The Risk of Major Stroke Within 30 Days 
was Higher after Surgical AVR than TAVI, while the 
Risk of Any Stroke or TIA was Similar  
Among matched 1,204 pairs of patients with severe 
aortic stenosis treated with AVR vs transfemoral (TF) 
TAVI, 30-day stroke (5.1% vs 3.7%; p=0.09) was similar, 
but 30-day major stroke (3.9% vs. 2.2%; p=0.018) was 
lower after TF-TAVI than AVR. In both groups, risk of 
stroke peaked in the first post-procedure day, followed by 
a near-constant low-level risk to 4 years. Major stroke was 
associated with a decline in quality of life at 1 year in both 
and TF-TAVI (Kapadia SR et al, J Am Coll Cardiol 
2018;72:2415-26).  
 
CIRT Trial: Negative Results / Methotrexate Did Not 
Reduce MACE in Patients with Stable CAD and DM 
and/or Metabolic Syndrome 
Among patients randomized (1:1) to low-dose metho-
trexate 15-20 mg/w (n=1,716) or placebo (n=1,695), all 
receiving folic acid 1 mg, the primary outcome of major 
adverse cardiac events (MACE) was 3.4/100 person-years 
for methotrexate vs 3.4/100 person-years for control 
(hazard ratio 1.01, p = 0.91). MACE plus hospitalization 
for unstable angina requiring revascularization was 4.1% 
vs 4.3%, p=0.67. Methotrexate did not reduce interleukin 
(IL)-1β, IL-6, hsCRP, or CV events compared with 
placebo among patients with established CAD and either 
diabetes or metabolic syndrome or both. Despite using a 
low dose, patients receiving methotrexate had a higher 
incidence of side effects such as transaminitis, leucopenia, 
anemia, and infections (Ridker et al, N Engl J Med 2018 
Nov 10; doi: 10.1056/NEJMoa1809798).  
 
TAVI: Paravalvular Leak and High Molecular Weight 
Multimers Defect of Von Willebrand Factor Detected 
by ADP Closure Time (CT-ADP) are Predictors of 
Major Hemorrhage Occurring > 30 Days After TAVI 
Among 372 TAVI patients surviving 30 days, the 
impact of ongoing primary hemostasis disorders on late 
major/life-threatening bleeding was evaluated by CT-
ADP, a surrogate marker of high molecular weight von 
Willebrand multimers proteolysis, defined as CT-ADP 
>180 s. Major bleeding occurred in 42 patients (11.3%) at 
a median of 383 days, was mainly gastrointestinal (42.8%) 
and was associated with increased overall mortality 
(hazard ratio - HR: 5.66; p< 0.001) and cardiac mortality 
(HR: 11.62; p< 0.001). A 2.5-fold higher bleeding rate was 
noted in patients with a CT-ADP > 180 s (27.4% vs 11.5%; 
p< 0.001). Regression analysis identified paravalvular leak 
(HR: 6.31; p< 0.0001) and CT-ADP > 180 s (HR: 3.08; 
p=0.0005) as predictors of major bleeding (Kibler M et al, 
J Am Coll Cardiol 2018;72: 2139-48).  
 
Soluble Suppression of Tumorigenesis-2 (sST2) is an 
Independent Predictor for All-Cause & CV Mortality, 
and Heart Failure (HF) Hospitalization in Chronic HF 
Soluble suppression of tumorigenesis-2 (sST2) is a 
biomarker related to inflammation and fibrosis. In 4,268 
HF patients (median age 68 years, 75% males, 65% with 
ischemic HF, 87% with LVEF<40%), median NT-
proBNP, hs-TnT, and sST2 were 1,360 ng/l, 18 ng/l, and 
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27 ng/l, respectively. Over a median of 2.4 years, among 
the 4,118 patients (96%) with available data, 1,029 (24%) 
were hospitalized at least once for worsening HF over 2.2 
years. The best sST2 cutoff for the prediction of all-cause 
and CV death and HF hospitalization was 28 ng/ml. In 
multivariate analysis, the risk of all-cause death, CV death, 
and HF hospitalization increased by 26%, 25%, and 30%, 
respectively, per each doubling of sST2, which was an 
independent prognosticator (Emdin M et al, J Am Coll 
Cardiol 2018;72:2309–20).  
 
GUIDE-IT: Guiding Therapy in Patients With Chronic 
HF and Reduced Ejection Fraction by Measurements 
of Plasma NT-proBNP Does Not Improve Clinical or 
Patient-Reported Outcomes and May Increase Cost 
Baseline variables were well balanced in the 446 
patients randomized to the NT-proBNP–guided therapy 
and 448 to usual care. Quality of life (QOL) measures 
improved over the first 6 months, but no evidence was 
found for a strategy-related difference at 2 years of follow-
up. Total winsorized costs averaged $5,919 higher in the 
biomarker-guided strategy over 15-month median follow-
up (Mark DB et al J Am Coll Cardiol 2018;72:2551–62).  
 
Framingham Heart Study Offspring Cohort: Rising 
Plasma Levels of Galectin-3 (Gal-3) are Associated 
With Incident Heart Failure (Both HFpEF and 
HFrEF), Cardiovascular Disease (CVD), and All-
Cause Mortality in Community-Dwelling Individuals 
Among 2,477 participants the following clinical 
correlates were associated with greater longitudinal 
increases in Gal-3 levels: age, female sex, hypertension, 
diabetes, body mass index, interim development of chronic 
kidney disease, and HF (p< 0.0001 for all). Change in Gal-
3 was associated with future HF (hazard ratio - HR: 1.39 
per 1-SD increase), CVD (HR: 1.29), and all-cause 
mortality (HR: 1.30). Change in Gal-3 was associated with 
both HF, HFpEF & HFrEF (p< 0.05 for both) (Ghorbani A 
et al, J Am Coll Cardiol 2018;72:3246–54).  
 
CoreValve U.S. Pivotal High-Risk Trial: In High-Risk 
Patients With Aortic Stenosis, TAVI With Self-
Expanding Bioprosthesis is Associated With Survival, 
Safety and Functional Outcomes at 5 Years Similar to 
Those With Surgical AVR 
A total of 797 patients were randomized, of whom 750 
underwent an attempted implant (TAVI=391, AVR=359). 
The overall mean age was 83 years, and the STS score was 
7.4%. All-cause mortality rates at 5 years were 55.3% for 
TAVI and 55.4% for AVR. Major stroke rates were 12.3% 
for TAVI and 13.2% for AVR. Mean aortic valve gradients 
were 7.1 ± 3.6 mmHg for TAVI and 10.9 ± 5.7 mmHg for 
AVR. No clinically significant valve thrombosis was 
observed. Freedom from severe valve degeneration was 
99.2% for TAVI and 98.3% for AVR (p=0.32), and 
freedom from valve reintervention was 97% for TAVI and 
98.9% for AVR (p=0.04). A pacemaker was implanted in 
33% of TAVI and 19.8% of AVR patients at 5 years 
(Gleason TG et al, J Am Coll Cardiol 2018;72:2687-96).  
 
COMMANDER-HF: Rivaroxaban (2.5 mg bid) Was 
Not Associated With a Lower Rate of Death, MI, or 
Stroke than Placebo Among Patients With Worsening 
Chronic Heart Failure (HF), Reduced LVEF, 
Coronary Artery Disease (CAD), and No AF 
Among 5022 patients with chronic HF, a LVEF of 
<40%, CAD, and elevated natriuretic peptides and who did 
not have AF, randomly assigned to rivaroxaban (2.5 mg 
bid) or placebo in addition to standard care, over a median 
of 21.1 months, the primary end point (death, MI, stroke) 
occurred in 25% vs 26.2%) (hazard ratio-HR; P=0.27). No 
significant difference in mortality was noted between the 
rivaroxaban and the placebo group (21.8% and 22.1%, 
respectively; HR, 0.98). The principal safety outcome 
occurred in 18 patients who took rivaroxaban and in 23 
who took placebo (HR, 0.80; P=0.48) (Zannad F et al, N 
Engl J Med 2018; 379:1332-42). 
 
Brugada Syndrome (BrS): Structural and Electrical 
Defects in the RVOT with Inflammation Playing a 
Crucial Role in These Changes and in the Evolution of 
the Arrhythmic Substrate  
Low-voltage areas (LVAs) were observed in 93% 
(unipolar map) and 50% (bipolar map) of BrS patients, 
with unipolar LVAs always larger than bipolar LVAs, 
always colocalized, and in all cases including the RVOT. 
RVOT histology was pathologic in 75% (80% myocardial 
inflammation). Among patients with abnormal bipolar 
map submitted to endomyocardial biopsy, 9 (81%) showed 
evidence of myocardial inflammation. Conversely, bipolar 
map was abnormal in 83% of patients with myocardial 
inflammation. Gene mutations were detected in 10 (33%) 
patients. Programmed ventricular stimulation was positive 
in 16 cases (53%). Myocardial inflammation was also 
more prevalent among inducible patients (83% vs 25% in 
noninducible; p=0.032) (Pieroni M et al, J Am Coll Cardiol 
2018;72:2747–57).  
 
ASPREE: Low-Dose Aspirin as Primary Prevention 
Strategy in Older Adults Increased Bleeding and Did 
Not Result in Lower Risk of Cardiovascular Disease  
Among 19,114 persons, 9525 assigned to aspirin and 
9589 to placebo, after a median of 4.7 years, the rate of 
cardiovascular disease was 10.7 events per 1000 person-
years in the aspirin group and 11.3 events per 1000 person-
years in the placebo group (hazard ratio-HR, 0.95). The 
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rate of major hemorrhage was 8.6 events per 1000 person-
years and 6.2 events per 1000 person-years, respectively 
(HR, 1.38; P<0.001) (McNeil JJ et al, N Engl J Med 2018; 
379:1509-18).  
 
ASPREE: Higher All-Cause Mortality Among Healthy 
Older Adults Who Received Daily Aspirin vs Placebo, 
Attributed Primarily to Cancer-Related Death 
Among 19,114 persons, 9525 assigned to aspirin and 
9589 to placebo, a total of 1052 deaths occurred over a 
median of 4.7 years. The risk of death was 12.7 events per 
1000 person-years in the aspirin group and 11.1 events per 
1000 person-years in the placebo group (hazard ratio-HR, 
1.14). Cancer was the major contributor to the higher 
mortality in the aspirin group, accounting for 1.6 excess 
deaths per 1000 person-years (3.1% vs 2.3%; HR 1.31) 
(McNeil JJ et al, N Engl J Med 2018; 379:1519-28). 
 
ASCEND: Aspirin Prevented Serious Vascular Events 
in Persons with Diabetes and no Evident CV Disease, 
Albeit with Increased Bleeding 
Among 15,480 randomized participants, over a mean 
of 7.4 years, serious vascular events occurred in a lower 
percentage of participants in the aspirin group than in the 
placebo group (8.5% vs 9.6%; rate ratio, 0.88; P=0.01). In 
contrast, major bleeding events occurred in 4.1% vs 3.2% 
(rate ratio, 1.29; P=0.003), with most of the excess being 
gastrointestinal bleeding and other extracranial bleeding. 
There was no significant difference between groups in the 
incidence of gastrointestinal tract cancer (2% vs 2.0%) or 
all cancers (11.6% vs 11.5%) (ASCEND study group, N 
Engl J Med 2018; 379:1529-39).  
 
MAIN-COMPARE: In Patients With Left Main (LM) 
Disease, PCI, Compared With CABG, Had Similar 
Rates of Death and Serious Composite Outcomes, But 
a Higher Rate of Target-Vessel Revascularization at 10 
Years / However, in the Late Cohort Comparing DES 
and Concurrent CABG, CABG Showed Lower 
Mortality and Serious Composite Outcome Rates 
Compared With DES Especially After 5 Years  
Among 2,240 patients with unprotected LM disease 
who underwent PCI (n=1,102) or CABG (n=1,138), there 
was no significant difference in adjusted risks of death and 
the composite outcome between the groups up to 10 years. 
The risk of target-vessel revascularization was higher in 
the PCI group. In the cohort comparing DES and 
concurrent CABG, the 2 study groups did not differ 
significantly in the risks of death and the composite 
outcome at 5 years. However, after 5 years, DES were 
associated with higher risks of death (hazard ratio-HR: 
1.35) and the composite outcome (HR: 1.46) compared 
with CABG (Park D-W et al, J Am Coll Cardiol 
2018;72:2813–22).  
 
Favorable Long-Term Survival After Echo-Guided 
Alcohol Septal Ablation in Symptomatic Patients With 
Hypertrophic Obstructive Cardiomyopathy (HOCM)  
Alcohol injection (2.1±0.4 cc) was performed in 952 
HOCM patients (age 55.7±14.9 years; 59.2% men; 73.3% 
NYHA class III or IV; 50.3% syncope; 10.3% sudden 
cardiac death in family). Maximal creatine kinase rise was 
872±489 U/l. Two (0.21%) patients died 3 and 33 days 
after ablation. Pacemaker was implanted in 100 (10.50%) 
patients. Echo gradients were acutely reduced from 63.9 ± 
38.2 mmHg to 33.6 ± 29.8 mmHg at rest and from 104.6 ± 
44.0 mmHg to 56.5 ± 41.0 mmHg at Valsalva (p< 0.0001, 
each). Over 6±5 years, 164 (17.2%) patients underwent 
reablation due to the planned staged procedure, 18 (1.9%) 
underwent surgical myectomy, and 49 (5.10%) underwent 
ICD implantation. Death occurred in 70 patients: non-
cardiovascular (CV) in 50, stroke-related in 6, and cardiac 
in 14 patients. Estimated 5-, 10- and 15-year survival was 
95.8/88.3/79.7%, survival free of CV events was 
98.6/96.5/92.3%, and survival free of cardiac events was 
98.9/97/96.5% (Batzner A et al, J Am Coll Cardiol 
2018;72:3087–94).  
 
PADIT Trial: Compared With Conventional Antibiotic 
Prophylaxis With Preprocedural Cefazolin in Patients 
Undergoing Implantation of Cardiac Electronic 
Devices (CIEDs), a More Aggressive Multicomponent 
Antibiotic Regimen Provided No Significant Efficacy 
Advantage in Preventing Device-Related Infections 
Conventional treatment was pre-procedural cefazolin 
(IV); incremental treatment was pre-procedural cefazolin 
plus vancomycin, intraprocedural bacitracin pocket wash, 
and 2-day post-procedural oral cephalexin. Among 19,603 
patients having a device, infection occurred in 99 patients 
(1.03%) receiving conventional treatment, and in 78 
(0.78%) receiving incremental treatment (odds ratio-OR: 
0.77; p=0.10). In high-risk patients, hospitalization for 
infection occurred in 1.23% receiving conventional and in 
1.01% receiving incremental antibiotics (OR: 0.82; 
p=0.26). Subgroup analysis did not identify relevant 
patient or site characteristics with significant benefit from 
incremental therapy (Krahn AD et al, J Am Coll Cardiol 
2018;72:3098–3109). 
 
Elevated Baseline and On-Statin Lipoprotein(a) Has an 
Independent Relation With Cardiovascular (CV) Risk  
Analyses of 7 statin trials (29,069 patients) (mean age 
62 years, 28% women) indicated that initiation of statin 
therapy reduced LDL cholesterol (mean change −39%) 
without a significant change in lipoprotein(a) – Lp(a). 
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Associations of baseline and on-statin treatment Lp(a) with 
CV disease risk were approximately linear, with increased 
risk at Lp(a) values of >30 mg/dL for baseline Lp(a) and 
>50 mg/dL for on-statin Lp(a). For baseline Lp(a), 
adjusted hazard ratios - HRs were 1.04 for 15-30 mg/dL, 
1·11 for 30-50 mg/dL, and 1.31 for >50 mg/dL; respective 
HRs for on-statin Lp(a) were 0.94, 1.06, and 1.43. HRs 
were almost identical after further adjustment for other risk 
factors. The association of on-statin Lp(a) with CV disease 
risk was stronger than for on-placebo Lp(a) (interaction 
p=0.010) and was more pronounced at younger ages 
(interaction p=0.008) without effect-modification by any 
other patient-level or study-level characteristics (Willeit P 
et al, Lancet 2018;392:1311-1320). 
 
ARISTOTLE Trial: Biomarkers, High-Sensitivity 
Troponin T (hsTnT), Growth Differentiation Factor-15 
(GDF-15), N-Terminal Pro-B-Type Natriuretic Peptide 
(NT-proBNP), and Interleukin-6 (IL-6) Were Some of 
the Strongest Predictors of Cause-Specific Death and 
May Improve the Ability to Discriminate Among 
Patients’ Risks for Different Causes of Death  
Biomarkers were measured at randomization in 14,798 
of 18,201 AF patients randomized to apixaban or warfarin. 
Over a median of 1.9 years, 1272 patients died: 652 (51%) 
cardiovascular (CV), 32 (3%) bleeding, and 588 (46%) 
non-CV/nonbleeding deaths. Among CV deaths, 255 
(39%) were sudden cardiac deaths, 168 (26%) heart failure 
deaths, and 106 (16%) stroke/systemic embolism deaths. 
Biomarkers were the strongest predictors of cause-specific 
death: a doubling of hsTnT was most strongly associated 
with sudden death (hazard ratio -HR, 1.48; P<0.001), NT-
proBNP with heart failure death (HR, 1.62; P<0.001), and 
GDF-15 with bleeding death (HR, 1.72; P=0.028). Prior 
stroke/systemic embolism (HR, 2.58; P>0.001) followed 
by hsTnT (HR, 1.45; P<0.0029) were the most predictive 
for stroke/ systemic embolism death (Sharma A et al, 
Circulation 2018;138:1666–1676).  
 
Cooper Center Longitudinal Study: In a Low 10-Year 
Risk Cohort With Long-Term Follow-Up, LDL-
Cholesterol and Non–HDL-Cholesterol ≥160 mg/dl 
Were Independently Associated With a 50-80% 
Increased Relative Risk of CVD Mortality  
Among 36,375 participants (72% men, median age 42) 
followed for a median of 26.8 years, 1086 CVD and 598 
CAD deaths occurred. Compared with LDL-C <100 
mg/dL, LDL-C categories 100 to 129 mg/dL (HR 1.4), 130 
to 159 mg/dL (HR 1.3), 160 to 189.9 mg/dL (HR 1.9), and 
≥190 mg/dL (HR 1.7) were associated with a significantly 
higher risk of CVD death and mean reductions in years free 
of CVD death of 1.8, 1.1, 4.3, and 3.9, respectively. After 
adjustment for CV risk factors, LDL-C categories 160 to 
189 mg/dL and ≥190 mg/dL remained independently 
associated with CVD mortality, with HRs of 1.7 and 1.5, 
respectively. In multivariable-adjusted models using non–
HDL-C <130 mg/dL as the reference, non–HDL-C 160 to 
189 mg/dL (HR 1.3), 190 to 219 mg/dL (HR 1.8), and ≥220 
mg/dL (1.5) were significantly associated with CVD death 
(Abdullah SM et al, Circulation 2018;138:2315–25).  
 
FRANCE-2 Registry: Good Durability of TAVI at 5 
Years  
Among 4201 patients the 5-year vital status was 
available for 95.5%; 88.1% had clinical evaluation or died. 
At 5 years, all-cause mortality was 60.8% (n=2478). The 
majority of CV events occurred in the first month after 
TAVI; incidence remained low thereafter, at <2% per year 
up to 5 years, except for heart failure rate which was 14.3% 
at 1 year, then decreased over time to <5% per year. The 
rate of severe structural valve deterioration (SVD) at 5 
years was 2.5% and of moderate/ severe SVD 13.3%. 
Mortality did not differ between patients with or without 
severe SVD (hazard ratio, 0.71; p=0.1). Among those with 
severe SVD, 1 patient (1.7%) experienced a stroke, and 8 
patients presented ≥1 heart failure event (13.3%) (Didier R 
et al, Circulation 2018;138:2597–2607). 
 
HEART Pathway (History, ECG, Age, Risk Factors, 
and Initial Troponin) is an Accelerated Diagnostic 
Protocol Designed to Identify Low-Risk Emergency 
Department (ED) Patients With Chest Pain for Early 
Discharge Without Stress Testing or Angiography  
Among 8474 adult ED patients with possible acute 
coronary syndrome (3713 pre-implementation and 4761 
post-implementation cohorts), the HEART pathway 
identified 30.7% as low risk; 0.4% of these patients 
experienced death or MI within 30 days. Hospitalization at 
30 days was reduced by 6% in the post-implementation vs 
pre-implementation cohort (55.6% vs 61.6%; odds ratio-
OR, 0.79). During the index visit, more MIs were detected 
in the post-implementation cohort (6.6% vs 5.7%; OR, 
1.36). Rates of death or MI during follow-up were similar 
(1.1% vs 1.3%; OR, 0.88) (Mahler SA et al, Circulation 
2018;138: 2456–68).  
 
Harmony Outcomes: In Patients With Diabetes and 
Cardiovascular (CV) Disease, Albiglutide was Superior 
to Placebo Regarding Major Adverse CV Events  
Among 9463 patients randomized to albiglutide 
(n=4731) or placebo (n=4732), over a median of 1.6 years, 
the primary outcome (CV death, MI or stroke) occurred in 
7% vs 9% at an incidence rate of 4.6 vs 5.9 events per 100 
person-years (hazard ratio -HR 0.78), which indicated that 
albiglutide was superior to placebo (p<0.0001 for non-
inferiority; p=0.0006 for superiority). The incidence of 
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acute pancreatitis (10 vs 7 patients), pancreatic cancer (6 
vs 5 patients), thyroid carcinoma (0 patients in both 
groups), and other serious adverse events did not differ 
between the two groups. There were 3 (<1%) deaths in the 
placebo group that were assessed to be treatment-related 
and two (<1%) deaths in the albiglutide group (Hernandez 
AF et al, Lancet 2018;392:1519-29).  
 
HFpEF: Not Just a Disease of the Elderly / It Also 
Occurs in Younger Patients Who are Often Obese, 
Have Fewer Comorbidities vs the Older, Yet Similar 
Filling Pressures and LVH / Better Quality of Life and 
Mortality, Yet Much Worse Mortality Compared With 
Matched Controls 
Among 1203 patients with heart failure with preserved 
ejection fraction (HFpEF), 37% were <65 years of age, 
more often male and obese (BMI ≥30 kg/m2; 36% in very 
young (<55 years) vs 16% in elderly) together with less 
renal impairment, AF, and hypertension (all P<0.001). Left 
ventricular filling pressures and prevalence of LVH were 
similar in very young and elderly HFpEF. Quality of life 
was better and death and heart failure hospitalization at 1 
year occurred less frequently (P<0.001) in the very young 
(7%) compared with elderly (21%) HFpEF. Compared 
with control subjects, very young HFpEF had a 3-fold 
higher death rate and twice the prevalence of hypertrophy 
(Tromp J et al, Circulation 2018;138:2763–73). 
 
CULPRIT-SHOCK: Among Patients With Acute MI 
and Cardiogenic Shock, the Risk of Death or Renal-
Replacement Therapy at 30 Days Was Lower With 
Culprit-Lesion-Only PCI Than With Immediate 
Multivessel PCI, While Mortality was Similar at 1 Year  
Among 706 patients randomly assigned to culprit-
lesion-only PCI or immediate multivessel PCI, at 30 days, 
the primary end point (death or renal failure) occurred in 
45.9% vs 55.4% (P=0.01). At 1 year, death rate was 50% 
vs 56.9% (relative risk-RR, 0.88). The rate of recurrent MI 
was 1.7% vs 2.1% (RR, 0.85), and the rate of a composite 
of death or recurrent MI was 50.9% vs 58.4% (RR, 0.87). 
Repeat revascularization occurred more frequently with 
culprit-lesion-only PCI (32.3% vs 9.4%; RR, 3.44), as did 
rehospitalization for heart failure (5.2% vs 1.2%; RR, 4.46) 
(Thiele H et al, N Engl J Med 2018; 379:1699-1710.  
 
LEADER: In Patients With Type 2 Diabetes (DM) and 
High Cardiovascular (CV) Risk, Liraglutide Reduced 
CV Outcomes Both in Patients With a History of MI/ 
Stroke and in Those With Established CV Disease 
Without MI/ Stroke, While it was Neutral in Patients 
With CV Risk Factors Alone  
Of the 9340 patients with DM and high CV risk 
randomized to liraglutide (1.8 mg or maximum tolerated 
dose) vs placebo with a median follow-up of 3.8 years. , 
3692 (39.5%) had a history of MI/stroke, 3083 (33.0%) 
had established atherosclerotic CV disease without 
MI/stroke, and 2565 (27.5%) had CV risk factors alone. 
Major adverse cardiovascular events (MACE) occurred in 
18.8% of patients with a history of MI/stroke (incidence 
rate, 5.0 per 100 patient-years), 11.6% of patients with 
established CV disease without MI/stroke (incidence rate, 
3.0 per 100 patient-years), and 9.8% of patients with CV 
risk factors alone (incidence rate, 2.6 per 100 patient-
years). Liraglutide reduced MACE in patients with a 
history of MI/stroke (17.3% vs 20.4%; hazard ratio-HR, 
0.85) and in those with established CV disease without 
MI/stroke (10.3% vs 12.9%; HR, 0.76) compared with 
placebo. In patients with risk factors alone, the HR for 
liraglutide vs placebo was 1.08 (p=NS) (Verma S et al, 
Circulation. 2018;138:2884-94).  
 
LEADER Trial: Liraglutide Added to Standard of 
Care Reduced the Risk for Major Cardiovascular 
Events (MACE) and All-Cause Mortality in Patients 
With Diabetes and Chronic Kidney Disease (CKD) 
In patients with eGFR <60 mL/min/1.73 m2 (n=2158) 
risk reduction for the primary composite cardiovascular 
(CV) outcome with liraglutide was greater (hazard ratio - 
HR, 0.69) vs those with eGFR ≥60 mL/min/1.73 m2 
(n=7182) (HR, 0.94; p=0.01). Risk reductions in those 
with eGFR <60 vs ≥60 mL/min/1.73 m2 were as follows: 
for nonfatal mi, HR, 0.74 vs HR, 0.93; for nonfatal stroke, 
HR, 0.51 vs HR, 1.07; for CV death, HR, 0.67 vs HR, 0.84; 
for all-cause mortality, HR, 0.74 vs HR, 0.90. Risk 
reduction for the primary composite CV outcome was not 
different for those with vs without baseline albuminuria 
(Mann JFE et al, Circulation 2018;138:2908–2918).  
 
ODYSSEY OUTCOMES: Among Patients With Prior 
Acute Coronary Syndrome (ACS) Receiving High-
Intensity Statin Therapy, the Risk of Recurrent 
Ischemic CV Events Was Lower Among Those Who 
Received Alirocumab vs Placebo  
Among 18,924 ACS patients receiving high-intensity 
statin and having LDL-cholesterol >70 mg/dl, randomly 
assigned to s.c. alirocumab (75 mg/2 weeks, n=9462) or 
placebo (n=9462), over a median of 2.8 years, a composite 
primary end-point event (CV death, MI, stroke, unstable 
angina) occurred in 9.5% vs 11.1% (hazard ratio-HR, 0.85; 
P<0.001). Death rate was 3.5% vs 4.1% (HR, 0.85). The 
absolute benefit of alirocumab with respect to the 
composite primary end point was greater among patients 
who had a baseline LDL cholesterol level of >100 mg/dl 
vs a lower baseline level. The incidence of adverse events 
was similar in the two groups, with the exception of local 
injection-site reactions (3.8% in the alirocumab group vs. 
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2.1% in the placebo group) (Schwartz GG et al, N Engl J 
Med 2018; 379:2097-2107).  
 
MITRA-FR: MitraClip Conferred No Benefit in 
Patients With Severe Secondary Mitral Regurgitation, 
Regarding Death or Unplanned Hospitalization for 
Heart Failure at 1 Year  
Among randomly assigned patients with severe 
secondary mitral regurgitation, a left ventricular ejection 
fraction 15-40%, and symptomatic heart failure, in a 1:1 
ratio, to MitraClip (n=152) or medical therapy alone 
(n=152), at 1 year, the rate of the primary outcome (death 
or unplanned hospitalization for heart failure) was 54.6% 
in the intervention group and 51.3% in the control group 
(odds ratio-OR, 1.16; P=0.53). The rate of death from any 
cause was 24.3% vs 22.4% (hazard ratio-HR, 1.11). The 
rate of unplanned hospitalization for heart failure was 
48.7% vs 47.4% (HR, 1.13) (Obadia J-F et al, New Engl J 
Med 2018;379:2297-2306). 
 
PURE Study: Dairy Consumption Was Associated 
With Lower Risk of Mortality and Major Cardio-
vascular (CV) Disease Events in a Diverse Multi-
national Cohort  
Among 136,384 individuals aged 35–70 years enrolled 
from 21 countries, higher intake of total dairy (>2 servings 
per day compared with no intake) was associated with a 
lower risk of the composite outcome of mortality or major 
CV events (CV death, MI, stroke, or heart failure) (HR 
0.84; ptrend=0.0004), total mortality (0.83; ptrend=0.0052), 
non-CV mortality (0.86; ptrend=0.046), CV mortality (0.77; 
ptrend=0.029), major CV disease (0·.8; ptrend=0.0001), and 
stroke (0.66; ptrend=0.0003). No significant association 
with MI was observed (HR 0.89; ptrend=0.163). Higher 
intake (>1 serving vs no intake) of milk (HR 0.90; 
ptrend=0.0529) and yogurt (0.86; ptrend=0.0051) was 
associated with lower risk of the composite outcome, 
whereas cheese intake was not significantly associated 
with the composite outcome (0.88; ptrend=0.1399). Butter 
intake was low and was not significantly associated with 
clinical outcomes (HR 1.09; ptrend=0.4113) (Dehgan M et 
al, Lancet 2018;392:2288-97). 
 
Maternal Use οf β-Blockers in the First Trimester is 
Not Associated With a Large Increase in the Risk for 
Overall Malformations or Cardiac Malformations  
First-trimester exposure to β-blockers was assessed in 
682 of 3577 (19.1%) women with hypertensive 
pregnancies in a Nordic cohort and 1668 of 14,900 
(11.2%) in a U.S. cohort. The pooled adjusted relative risk 
(RR) and risk difference per 1000 persons exposed 
(RD1000) associated with β-blockers were 1.07 and 3.0, 
respectively, for any major malformation; 1.12 and 2.1 for 
any cardiac malformation; and 1.97 and 1.0 for cleft lip or 
palate. For CNS malformations, the adjusted RR was 1.37 
and the RD1000 was 1.0 (based on U.S. cohort data only). 
(Bateman BT et al, Ann Intern Med 2018; 169:665-673).  
 
Comparative Safety and Effectiveness of Direct Oral 
Anticoagulants (DOACs): At Least as Effective and 
Safe as Warfarin for Patients With Nonvalvular AF  
Analysis of data from 220 articles indicated that 
dabigatran and apixaban were superior and rivaroxaban 
and edoxaban were similar to warfarin in preventing stroke 
or systemic embolism. Apixaban and edoxaban were 
superior and rivaroxaban and dabigatran were similar to 
warfarin in reducing the risk for major bleeding. Treatment 
effects with dabigatran were similar in patients with renal 
dysfunction (interaction P > 0.05), and patients <75 years 
had lower bleeding rates with dabigatran (interaction P < 
0.001). Apixaban had a consistent treatment benefit in 
many subgroups (renal impairment, diabetes, and prior 
stroke) (interaction P > 0.05 for all). The greatest bleeding 
risk reduction was observed in patients with a glomerular 
filtration rate <50 mL/min/1.73 m2 (P = 0.003). Similar 
treatment effects were observed for rivaroxaban and 
edoxaban in patients with prior stroke, diabetes, or heart 
failure (interaction P > 0.05 for all) (Lowenstern A et al, 
Ann Intern Med 2018;169:774-787).  
 
An Increased Risk for Venous Thromboembolism 
(VTE) in Patients With Rheumatoid Arthritis (RA), 
Psoriasis and Psoriatic Arthritis (PsA) and this Risk 
Remained Elevated After Adjustment for Established 
VTE Risk Factors in RA and Mild Psoriasis  
Among patients with PsA (n = 12,084), RA 
(n = 51,762), psoriasis (n = 194,288) and matched controls 
(n = 1,225,571), patients with RA (with and without a 
disease modifying anti-rheumatic drug - DMARD 
prescription) and patients with mild psoriasis had 
significantly elevated risks of VTE (HR 1.35, 1.29, and 
1.07, respectively) after adjusting for traditional risk 
factors. Severe psoriasis and PsA prescribed a DMARD 
had an elevated, but not statistically significant, risk for 
VTE. Findings were similar for deep vein thrombosis. The 
risk of pulmonary embolism was elevated in RA, severe 
psoriasis and PsA patients prescribed a DMARD (Ogdie A 
et al, Eur Heart J 2018;39:3608-14).  
 
Sudden Death Represents the Largest Proportion of 
Cardiovascular (CV) Deaths After 30 Days Among 
Patients Enrolled in CV Clinical Trials With Non-ST 
Elevation Acute Coronary Syndromes (NSTE-ACS) 
Of the 2606 patients (82.8%) with known modes of 
death among 66,252 patients with NSTE-ACS, over a 
median of ~1 year, 75.1% were related to CV event, 3% 
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were related to a bleeding event (including intracranial 
hemorrhage), and 21.8% were related to a non-CV/non-
bleeding event. The most common modes of CV death 
were sudden death (SD) and recurrent myocardial 
infarction (MI) (36.4% and 23.4%, respectively, of CV 
deaths). The proportion of CV deaths related to recurrent 
MI was higher in the first 30 days than afterwards (30.6% 
vs. 18.7%), whereas the proportion of SD was lower in the 
first 30 days (21.6% vs. 46.2%) (Berg DD et al, Eur Heart 
J 2018;39:3810-20). 
 
BIOSTATCHF: The Presence of Atrial Fibrillation 
(AF) is Associated With a Homogeneously Elevated 
Cardiovascular Risk Marker Profile in Patients With 
HFrEF, Whereas in HFpEF, the Presence of AF is 
Associated With a More Scattered Risk Marker 
Profile, Suggesting Differences in Pathophysiological 
Mechanisms of AF in These Two HF Groups 
 
Among 2152 patients with heart failure (HF) with 
reduced ejection fraction (EF) (HFrEF) (EF< 40%), of 
whom 1419 were in sinus rhythm (SR) and 733 had AF, 
and 524 patients with HF with preserved EF (HFpEF) (EF 
>50%), of whom 286 in SR and 238 with AF, the 
circulating risk marker pattern observed in HFrEF was 
different than the pattern in HFpEF. In HFrEF, AF was 
associated with higher levels of 77 of 92 (84%) risk 
markers compared to SR; whereas in HFpEF, many more 
markers were higher in SR than in AF. Over a median 
follow-up of 21 months, AF was associated with increased 
mortality risk (hazard ratio - HR of 1.27, P= 0.002); there 
was no significant interaction between heart rhythm and 
EF group on outcome (Santema BT et al, Eur Heart J 
2018;39:3867-75).  
 
AF Prevalence Increases With Increasing Ejection 
Fraction (EF) but its Association With Worse 
Cardiovascular Outcomes, Remained Significant in 
Patients with HFpEF & HFmrEF, but not in Those 
with HFrEF 
Among 14,964 HF patients (age 66 ± 13 years, 67% 
male; 53% HFrEF, 21% HFmrEF, 26% HFpEF), the 
prevalence of AF was 27% in HFrEF, 29% in HFmrEF, 
and 39% in HFpEF, associated with older age, lower 
functional capacity, and heightened physical signs of HF. 
Crude rates of mortality and HF hospitalization were 
higher in patients with AF compared to SR, in each EF 
subtype. The hazard ratio of AF for HF hospitalizations 
was: 1.036 (P = 0.652) in HFrEF, 1.430 (P = 0.011) in 
HFmrEF, and 1.487 (P < 0.001) in HFpEF; and for 
combined all-cause death or HF hospitalizations: 0.957 
(P = 0.502), 1.302 (P = 0.014), and 1.365 (P < 0.001), 
respectively. In patients with HFrEF, AF was not 
associated with worse outcomes in those presenting with 
either an acute or a chronic presentation of HF (Zafrir B et 
al, Eur Heart J 2018;39:4277-84).  
 
An Increased Risk of Ischemic Stroke or TIA Was 
Observed in Patients With Electrical Isolation of the 
Left Atrial Appendage (LAA)  
In 39 patients with LAA isolation, a higher rate of 
ischemic stroke or TIA was observed, compared to those 
without LAA isolation (n=2313) (log-rank, P <0.001; 
hazard ratio – HR 23.6; P < .001). There were significant 
differences in the baseline characteristics of the 2 groups, 
including type of AF (87.2% vs 39.4% patients with and 
without LAA isolation had nonparoxysmal AF). LAA 
isolation was found to be a significant risk factor for 
ischemic stroke or TIA (HR 11.3; P < .001). Propensity 
score–matched analysis also revealed an increased risk of 
ischemic stroke or TIA in patients with LAA isolation 
compared with those without LAA isolation (log-rank, P = 
0.001). The LAA flow velocity of post-LAA isolation 
status was similar in the 2 groups indicating that it is not a 
reliable marker to predict future ischemic events (Kim 
YG et al, Heart Rhythm 2018;15:1746-53).  
 
Anti-Desmoglein-2 (DSG2) Antibodies: a Sensitive & 
Specific Biomarker for Arrhythmogenic Right 
Ventricular Cardiomyopathy (ARVC) 
Among ARVC patients and controls evaluated for 
antibodies to cardiac desmosomal cadherin proteins, anti-
desmoglein-2 (DSG2) antibodies were identified in 12/12 
and 25/25 definite ARVC cohorts and 7/8 borderline 
subjects. Antibody was absent in 11/12, faint in 1/12, and 
absent in 20/20 of two controls. Anti-DSG2 antibodies 
were present in 10/10 Boxer dogs with ARVC, and absent 
in 18/18 without. In humans, the level of anti-DSG2 
antibodies correlated with the burden of PVCs (r = 0.70), 
and antibodies caused gap junction dysfunction, a common 
feature of ARVC, in vitro. Anti-DSG2 antibodies were 
present in ARVC patients regardless of whether a mutation 
was identified, or which mutation was present. A disease-
specific DSG2 epitope was identified (Chatterjee D et al, 
Eur Heart J 2018;39:3932-44).  
 
BRUISE CONTROL-2: Either a Continued or an 
Interrupted DOAC Management Strategy Seems 
Reasonable at the Time of Device Implantation 
A total of 590 AF patients with CHA2DS2-VASc score 
≥2 planned for elective device (pacemaker or 
defibrillator) surgery, were randomly assigned to 
continued (12h median time between pre- and post-
operative DOAC doses) vs interrupted DOAC (dabigatran, 
rivaroxaban, or apixaban) (72h median time). Clinically 
significant hematoma occurred in of 7 of 328 (2.1%) 
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patients in the continued DOAC arm and 7 of 334 (2.1%) 
patients in the interrupted DOAC arm (P = 0.97). 
Complications were uncommon, and included one stroke 
and one symptomatic pericardial effusion in each arm 
(Birnie DH et al, Eur Heart J 2018;39:3973-79).  
 
Higher Overall and Major Complication Rates than 
Previously Reported for AF Ablations in Germany 
in 2014/Inordinately High Rates of Life-Threatening 
Complications for Atrial Flutter Ablations 
Among 33,353 cases undergoing ablation for atrial 
fibrillation and atrial flutter in Germany in 2014, for left 
atrial ablations (n=19,514), the overall complication rate 
ranged from a mean of 11.7% to 13.8% depending on type 
and site of applied energy, including major complications 
ranging from 3.8% to 7.2%. Complication rates were lower 
for atrial flutter ablations (n=13,871, 10.5%; P < 0.001), 
however, major complications occurred more frequently 
(7.4%; P < 0.001) with a 4-fold more common in-hospital 
death following right than left atrial ablations (47 vs 18 
cases, 0.34% vs 0.09%; P < 0.001). Fewer complications 
occurred in centers performing >100 vs ≤100 left atrial 
ablations annually (12.7% vs 16.4%; P < 0.002) (Steinbeck 
G et al, Eur Heart J 2018;39:4020-29).  
 
Important Review and Other Articles  
 
● 2018 ACC/AHA Cholesterol Guidelines (Grundy SM et al, J 
Am Coll Cardiol. 2018 Nov 8. pii: S0735-1097(18)39034-X. 
doi: 10.1016/j.jacc.2018.11.003. [Epub ahead of print]) 
 
● 2017 AHA/ACC/HRS Guideline for Management of Patients 
With Ventricular Arrhythmias and the Prevention of Sudden 
Cardiac Death (Al-Khatib SM et al, Circulation. 2018;138: 
e272-e391.) 
 
● ACC/AHA Hypertension Guidelines (Whelton PK et al, 
Circulation. 2018;138:e484-e594) 
 
● ACC/AHA Bradycardia Guidelines (Kusumoto FM et al, 
Circulation. 2018 Nov 6: CIR0000000000000628. doi: 
10.1161/CIR.0000000000000628. [Epub ahead of print]) 
 
● Comparison of American and European Guidelines on Dual 
Antiplatelet Therapy (Capodanno D et al, J Am Coll Cardiol 
2018;72:2915-31) 
 
● Stress cardiomyopathy (Medina de Chazal H et al, J Am Coll 
Cardiol 2018;72:1955-71) 
 
● Air pollution and cardiovascular disease (Rajagopalan S et al, 
J Am Coll Cardiol 2018;72:2054-70)  
 
● Arrhythmic mitral valve prolapse (Miller MA et al, J Am Coll 
Cardiol 2018;72:2904-14) 
 
● LBBB (Auffret V et al, J Am Coll Cardiol 2018;72:3177-88) 
 
● Modernized Classification of Antiarrhythmic Drugs (Lei M et 
al, Circulation 2018; 138:1879–1896) 
 
● Thrombogenic & arrhythmogenic roles of left atrial appendage 
in AF (Di Biase L et al, Circulation 2018; 138:2036–50) 
 
● 2018 AHA Focused Update on ACLS Use of Antiarrhythmic 
Drugs During and Immediately After Cardiac Arrest (Panchal 
AR et al, Circulation 2018; 138:e740–e749)  
 
● 2018 ILCOR Statement on CPR (Soar J et al, Circulation 
2018; 138: e714–e730) 
 
● 2018 AHA Focused Update on Pediatric ALS (Duff JP et al, 
Circulation 2018; 138: e731–e739) 
 
● Left ventricular assist devices (Han JJ et al, Circulation. 2018; 
138:2841–2851) 
 
● European recommendations for participation in competitive 
sports of athletes with arterial hypertension (Niebauer J et al, Eur 
Heart J 2018; 39:3664-71) 
 
FDA News (2018) 
 
18/4/2018: The US FDA gave full approval to Boehringer 
Ingelheim’s idarucizumab (Praxbind) to reverse the 
anticoagulant effect of dabigatran (Pradaxa) in the event of 
urgent surgery or life-threatening or uncontrolled bleeding. The 
FDA had granted accelerated approval to idarucizumab in 
October 2015, with continued approval contingent upon the 
results of the recently completed RE-VERSE AD trial.  
 
4/5/2018: The FDA approved andexanet alpha (Andexxa, 
Portola Pharmaceuticals) (coagulation factor Xa (recombinant) 
inactivated-zhzo) to reverse the anticoagulation effects of factor 
Xa inhibitors when needed due to life-threatening or 
uncontrolled bleeding 
 
18/7/2018: The FDA keeps updating health care professionals 
and consumers following an FDA press release about voluntary 
recalls of several drug products containing valsartan. The 
recalled products contain an impurity, cancer-causing N-
nitrosodimethylamine (NDMA), in the drug manufactured by 
Zhejiang Huahai Pharmaceuticals, Linhai, China.  
 
27/11/2018: FDA alerted patients and health care professionals 
to Teva Pharmaceuticals’ voluntary recall of valsartan-
containing products manufactured by Mylan Pharmaceuticals.  
 
12/12/2018: The FDA has updated its testing methods to detect 
NDMA and NDEA impurities –These methods were validated 
with respect to valsartan drug substances and drug products 
 
19/12/2018: FDA is publishing interim acceptable intake levels 
of nitrosamine impurities in angiotensin II receptor blockers 
(ARBs) for manufacturers to use to ensure their finished drug 
products are safe for patients. 
 
20/12/2018: An FDA review found that fluoroquinolone 
antibiotics can increase the occurrence of rare but serious events 
of aortic dissections, or ruptures of an aortic aneurysm  
 
20/12/2018: FDA is alerting patients and health care 
professionals to Torrent Pharmaceuticals’ voluntary recall of 
two lots of losartan potassium 100 mg tablets due to N-Nitroso-
diethylamine (NDEA) in the losartan active pharmaceutical 
ingredient (API) manufactured by Hetero Labs Limited.  
